One Brave Idea™ is an innovative new collaborative research initiative focused on achieving extraordinary breakthroughs in the fight against the devastating global burden of coronary heart disease and its consequences.
In October 2016, Dr. Calum MacRea was selected as the One Brave Idea award recipient. Over the next five years, he and his world-class team who, over the next five years, will explore critical genetic and molecular factors that put individuals at risk for coronary heart disease. This work will enable great leaps toward our goal of achieving extraordinary breakthroughs in the fight against CHD.
The American Heart Association and Verily, with support from AstraZeneca, collectively committed $75 million, and guidance, mentorship and resources over at least five years to support a groundbreaking research idea aimed at preventing or reversing coronary heart disease and, ultimately, improving and restoring cardiovascular health. Verily’s and Astra Zeneca’s individual investments in One Brave Idea represent the two single largest contributions received by the AHA in its 90 year history, and demonstrate the compelling nature of this scientific opportunity
In January 2016, we launched a worldwide search to find a visionary leader with a brave idea to end coronary heart disease by focusing on causative factors and consequences, cardiovascular risk factors, and with the ultimate goal of designing and implementing novel strategies to prevent or reverse the causes and drivers of coronary heart disease.
After reviewing hundreds of submissions from researchers around the world, we selected Dr. Calum MacRae, chief of cardiovascular medicine at Brigham and Women’s Hospital in Boston, his renowned research team as the recipients of the One Brave Idea™ $75 million research funding opportunity.
Click HERE to view the archived virtual press conference featuring Dr. MacRae and members of the One Brave Idea Joint Leadership Group from the American Heart Association, Verily and AstraZeneca.
The American Heart Association and Verily, with support from AstraZeneca, collectively committed $75 million over at least five years to support a groundbreaking research idea aimed at preventing or reversing coronary heart disease and, ultimately, improving and restoring cardiovascular health.
In addition to the funding, representatives from the from American Heart Association, Verily and AstraZeneca, who form the One Brave Idea Joint Leadership Group, pledged to provide guidance, mentorship and substantial resources to bring the winning research idea to fruition
The American Heart Association is devoted to saving people from heart disease and stroke – the two leading causes of death in the world. We team with millions of volunteers to fund innovative research, fight for stronger public health policies, and provide lifesaving tools and information to prevent and treat these diseases.
Verily is a life sciences research and engineering organization focused on improving healthcare outcomes by applying the latest scientific and technological advances to significant problems in health and biology. By combining unparalleled capabilities in data organization and analytics services with robust scientific and product engineering expertise, Verily is targeting the dual objectives of creating tools and user-friendly platforms that capture a deeper and broader set of health data, and organizing the data so that it is useful and actionable. Verily partners with leading life sciences, medical device, and government organizations to leverage deep domain expertise and resources that enable exponentially faster development, meaningful advancements, and deployment at scale.
Committed to following the science and with a more than 100 year legacy in cardiovascular disease research, AstraZeneca works closely with a wide variety of partners and others to understand challenges and assess how skills and resources can be combined to improve cardiovascular health. They are pleased and honored to join this research challenge and initiative with significant support to help end coronary heart disease and improve cardiovascular health.